In conclusion, to our best knowledge that we are the first to use both cell and animal models to systemically demonstrate that metformin inhibits bladder cancer progression by inhibiting cancer stem cell repopulation through the COX2/PGE2/STAT3 axis. This evidence concerns the gene PTGS2 and urinary bladder carcinoma.